Rexahn Pharma Reports Positive Phase 2 Data for Archexin

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stagebiopharmaceutical company focused on developing multi-indication therapeuticsin oncology and CNS, today announced top-line results from a Phase II clinicalstudy of Archexin^®, its clinical-stage oncology drug candidate. Archexin isbeing developed as a potential first-in-class inhibitor of the Akt proteinkinase (Akt) in cancer cells.The open label 2-stage study was designed to assess the safety and efficacy ofArchexin in combination with gemcitabine. Stage 1 was the dose finding portionand stage 2 was the dose expansion portion using the dose identified in stage1 to be administered with gemcitabine. The study enrolled 31 subjects aged18-65 years with metastatic pancreatic cancer at four centers in the UnitedStates and five centers in India. The primary endpoint was overall survivalfollowing 4 cycles of therapy with a 6-month follow-up.